Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnRoute+ study in stage I-II colon cancer with nodal micrometastases
NL-OMON36641Phase 3Withdrawn
- Sponsor
- Jeroen Bosch Hospital
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by Jeroen Bosch Hospital. Primary endpoint: 3-year disease-free survival. Planned start Jul 2010; status: withdrawn.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON36641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36641.